Graft versus host disease (GvHD) occurs following a donor stem cell transplant. GvHD is a frequent complication of bone marrow or stem cell transplantation using tissue from another person. Before transplantation, cells from possible donors are screened to understand how well donors’ cells match with that of the recipients. Stem cell transplantation is used to treat various diseases related to the blood. The procedure involves replacing diseased or damaged cells with healthy cells from a donor. A donor's stem cells contain white blood cells (T cells) that help fight infections.  Graft versus host disease occurs when these T cells attack the patient’s own tissues, as the donated cells recognize the patient’s body cells as foreign tissue. Graft versus host disease affects different parts of the patient’s body. It most commonly affects the digestive system, liver, and skin. It is tough to predict who might develop graft versus host disease after a bone marrow or stem cell transplant. Chances of a graft versus host disease are reduced or symptoms are milder if the donor’s cells match closely with that of the recipient's.

Graft versus host disease is a major cause of morbidity and mortality following stem cell transplants. Research findings suggest that even after treatments with intensive immunosuppressive therapy, 50% to 70% of patients transplanted from unrelated donors and 30% to 50% of patients transplanted from fully matched sibling donors develop some level of graft versus host disease. At present, the global graft versus host disease treatment market is expanding, due to a rise in the prevalence and incidence of cancer patients. These patients are usually under chemotherapy. The global graft versus host disease treatment market is also driven by bone marrow transplants surgeries performed globally for specific types of cancers. Rise in allogeneic type of stem cell transplants is expected to boost the graft versus host disease treatment market. However, costs related to authorization and clinical trials of treatment therapies for GvHD are expected to restrain the global graft versus host disease treatment market.

The global graft versus host disease treatment market can be segmented based on disease, product, and region. Based on disease, the graft versus host disease treatment market can be categorized into acute graft versus host disease (aGvHD) and chronic graft versus host disease (cGvHD). In terms of product, the global graft versus host disease treatment market can be classified into mTOR inhibitors, tyrosine kinase inhibitors, monoclonal antibodies, Etanercept, and Thalidomide.

Based on region, the global graft versus host disease treatment market can be categorized into North America, Asia Pacific, Europe, Latin America, and Middle East & Africa. In terms of region, the graft versus host disease treatment market in North America and Asia Pacific is estimated to expand at a rapid rate due to a large incidence and prevalence rate of the global graft versus host disease. For instance, a research study suggests that around 30% to 50% of hematopoietic stem cell transplant (HSCT) recipients develop acute GVHD. That translates to 5500 patients/year who will develop acute GVHD. Eventually, around 50% of patients with acute graft versus host disease have manifestations of chronic graft versus host disease. The global graft versus host disease treatment market in Europe is also estimated to expand due to a rise in the geriatric population with cancer disease, improvements in medical research, and increase in clinical trials. The graft versus host disease treatment market in various geographies is specifically driven by the adoption of advanced technologies in cancer treatment, increase in awareness about diseases, and rise in the number of chemotherapy treatments.

Some of the key players operating in the global graft versus host disease treatment market include Novartis AG, Bristol-Myers Squibb, Pfizer, F. Hoffmann-La Roche, AbbVie, Astellas Pharma, Merck & Co., Takeda Pharmaceutical, Abbott, and Eli Lilly.

The report offers a comprehensive evaluation of the market. It does so via in-depth qualitative insights, historical data, and verifiable projections about market size. The projections featured in the report have been derived using proven research methodologies and assumptions. By doing so, the research report serves as a repository of analysis and information for every facet of the market, including but not limited to: Regional markets, technology, types, and applications.

The study is a source of reliable data on:

  • Market segments and sub-segments
  • Market trends and dynamics
  • Supply and demand
  • Market size
  • Current trends/opportunities/challenges
  • Competitive landscape
  • Technological breakthroughs
  • Value chain and stakeholder analysis

The regional analysis covers:

  • North America (U.S. and Canada)
  • Latin America (Mexico, Brazil, Peru, Chile, and others)
  • Western Europe (Germany, U.K., France, Spain, Italy, Nordic countries, Belgium, Netherlands, and Luxembourg)
  • Eastern Europe (Poland and Russia)
  • Asia Pacific (China, India, Japan, ASEAN, Australia, and New Zealand)
  • Middle East and Africa (GCC, Southern Africa, and North Africa)

The report has been compiled through extensive primary research (through interviews, surveys, and observations of seasoned analysts) and secondary research (which entails reputable paid sources, trade journals, and industry body databases). The report also features a complete qualitative and quantitative assessment by analyzing data gathered from industry analysts and market participants across key points in the industry’s value chain.

A separate analysis of prevailing trends in the parent market, macro- and micro-economic indicators, and regulations and mandates is included under the purview of the study. By doing so, the report projects the attractiveness of each major segment over the forecast period.

Highlights of the report:

  • A complete backdrop analysis, which includes an assessment of the parent market
  • Important changes in market dynamics
  • Market segmentation up to the second or third level
  • Historical, current, and projected size of the market from the standpoint of both value and volume
  • Reporting and evaluation of recent industry developments
  • Market shares and strategies of key players
  • Emerging niche segments and regional markets
  • An objective assessment of the trajectory of the market
  • Recommendations to companies for strengthening their foothold in the market   

Note: Although care has been taken to maintain the highest levels of accuracy in TMR’s reports, recent market/vendor-specific changes may take time to reflect in the analysis.